The Clorox Company

CLX Consumer Defensive Household & Personal Products

The Clorox Company’s revenue for fiscal 2026 (year ended June 2026) was $6.7 billion, down 5.41% from fiscal 2025.

Revenue
+33.3%
EPS
+118.9%
Free cash flow
+84.2%
Total debt
+60.3%

Quarter to September 2026, against a year earlier

100.23 0.53 +0.53%
Market cap
$12.1B
P/E
17.8×
Fwd P/E
15.6×
Dividend yield
5.01%
F-score
4/9
Altman Z
2.10
Beneish M
−2.43
Dividend safety
26/100

The Clorox Company (CLX) valuation and DCF model

What the price implies · reverse DCF

At $100.23 the price implies free cash flow after share-based pay growing 14.6% a year for ten years.

Free cash flow after share-based pay grew −1.1% a year over the last ten years, −6.9% over the last five. The price asks for 15.7 points a year more than its ten-year rate. The industry’s median company is priced for 10.7%.

In June 2017 the price assumed 13.0% a year; The Clorox Company went on to grow free cash flow after share-based pay −5.3% a year to FY2026.

Price implies
14.6%
Last 5 years, reported
−6.9%
Last 10 years, reported
−1.1%
Industry median implies
10.7%

The headline discounts the last twelve months’ free cash flow after share-based pay at 9.0% for ten years and grows it 2.5% a year after that, the same for every company, so the figure compares across the market (how a reverse DCF works).

The other way round · DCF
The price needs
14.6% a year for ten years
$100.23
today’s price
Its base case
−1.1% a year for five years, then −0.7%
$9.55
90.5% below today’s price

Both are growth in free cash flow after share-based pay, discounted at 9.0%, with 2.5% a year after year ten.

Base case on its own ten-year record The Clorox Company’s own growth, carried forward

Its assumptions

Powerpack lets you start from a scenario and type over any of them.

The base case’s inputs, which Powerpack lets you change
1 · Cash flow to equity
the four quarters to September 2026, from the 10-Q and 10-K filings, before share-based pay

Yearly growth in cash flow. It usually slows as the company matures.

Today’s price implies free cash flow after share-based pay growing 14.6% a year for ten years.

2 · Rates

Cost of equity is the yearly return shareholders require, typically 8–11%. Terminal growth is growth forever after year 10, usually near long-run inflation, 2–3%.

3 · Per share

Diluted shares outstanding. Net debt, under Advanced inputs, is taken off before dividing.

Advanced inputs
negative is net cash
new shares the cash flow does not pay for

Against The Clorox Company’s own cost of capital: risk-free 4.3% + beta 0.59 × equity premium 4.5% = 7.0% cost of equity; weighted, 7.0%.

Use 7.0%
Equity value $1.17b ▼ below market cap $12.22b
Base case value per share $9.55 equity value ÷ 121.97m shares
Current price $100.23 market price per share
Below today’s price 90.5% downside at the base case’s assumptions

How we got there$2.49b 10 years of cash to equity+$2.48b terminal value−$3.80b net debt=$1.17b equity value÷121.97m shares=$9.55 per share

Valuation against its own history

Today’s multiple against its 5- and 10-year averages and the industry median (Household & Personal Products).

Multiple Current 5Y avg 10Y avg vs 10Y avg Industry median vs industry 10Y range
P/E 17.79× 49.18× 38.96× 54% below 25.45× 30% below
P/FCF 26.71× 26.11× 25.52× 5% above 20.67× 29% above
P/B 100.01× 52.29× 41.25× 142% above 2.43× 4007% above
EV/EBITDA 12.10× 17.01× 17.51× 31% below 13.40× 10% below
EV/Sales 2.21× 2.54× 3.01× 27% below 1.24× 78% above
22.11×54.90×87.69×120.48×10Y avg 38.96×2018201920202021202220232024202520262026

CLX trades at 17.79× P/E, against a 10-year average of 38.96× (range 17.79×–130.36×). That is cheaper than 100% of the last 9 year-end readings; re-rating to the average implies $219.46 per share.

Every growth rate on this page is the business’s — its cash flow, FFO or dividend — never its share price’s. A discounted-cash-flow model is only as good as its assumptions. Figures from the 10-K and 10-Q filings. Not investment advice.